SynthesisReviews in cardiovascular medicine2025
Myocarditis in Hypertrophic Cardiomyopathy: Incidence and Contribution to Disease Progression and Outcome.
Synthesis in Reviews in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Curcumol alleviates cardiac and cerebral injury caused by encephalomyocarditis virus (EMCV) in Kunming mice via suppressing NF-κB/NLRP3 inflammasome pathway.Frontiers in pharmacology · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Myocardial diseases such as myocarditis and cardiomyopathies are clinically important and can cause complications such as heart failure and arrhythmias, which increase the risk of death. The combination of myocarditis with cardiomyopathy is difficult to diagnose because their manifestations often overlap, and multiple myocardial diseases are usually not included in the diagnostic search. Hypertrophic cardiomyopathy (HCM) is the most common cardiomyopathy; however, few studies have examined the combination of myocarditis and HCM, thereby highlighting the importance of this problem. This article aimed to analyze the influence of myocarditis on clinical features and outcomes in patients with HCM. Methods: A literature search was performed using PubMed and the Scientific Electronic Library eLIBRARY.ru databases. Relevant studies, published until November 2023, were analyzed in detail. Studies were selected in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards. Results: Twelve studies (three original articles and nine clinical cases) were isolated from a total cohort of 1504 publications and were included in the study. The prevalence of myocarditis in HCM ranged from 23.5% to 46.7%. The presence of concomitant myocarditis in patients with HCM was associated with heart failure progression, worsening of ventricular arrhythmias, and an increased risk of sudden cardiac death. Conclusions: The incidence of myocarditis in HCM is high. Early detection and treatment of myocarditis in patients with HCM can slow the progression of heart failure rhythm disturbances and improve the disease prognosis. The PROSPERO Registration: The systematic review was registered in the International Prospective Register of Systematic Reviews PROSPERO (CRD42024499672, https://www.crd.york.ac.uk/PROSPERO/view/CRD42024499672).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.